# SMART CARD: Metformin IR

**Card ID:** MED_DM_BIG_001
**Version:** 0.5
**Last Updated:** 2025-12-13
**Status:** Pre-release (v1.0 = first production deployment)

---

# üì± AT-A-GLANCE (20 seconds)

```
METFORMIN IR | 500mg ‚Üí 1000mg | TWICE DAILY | WITH FOOD
‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
Take: ‚úì Breakfast  ‚úì Dinner  (always with food)

üü¢ Week 1-2:  500mg  +  500mg
üü° Week 3-4:  500mg  + 1000mg
üü£ Week 5+:  1000mg  + 1000mg  ‚Üê target

Watch: Stomach upset (normal first 2-4 wks) ‚Üí improves
Stop & call: Breathing trouble | Severe pain | Very cold

Labs: A1c q3mo | eGFR q3-6mo | B12 yearly
Goal: A1c < 7.0% in ~3 months
‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
```

---

# üì± CONDENSED VIEW

> Your everyday quick guide.

## WHAT YOU'RE DOING
Taking Metformin twice daily to lower your blood sugar and protect your heart.

## WHY THIS MATTERS
**Your goal:** [Your own words - what you want to achieve]

**Why this medication:** First-choice diabetes medication for over 60 years. Lowers blood sugar safely, protects your heart, and doesn't cause weight gain.

## HOW TO DO IT
1. Take one pill **with breakfast**
2. Take one pill **with dinner**
3. **Always eat food** when you take it
4. Swallow whole with water

**Tip:** Keep pills next to your coffee maker or dinner plate.

## DOSE PROGRESSION

```
üü¢ Week 1-2 ‚Üí 500mg AM  +  500mg PM   (starting)
üü° Week 3-4 ‚Üí 500mg AM  + 1000mg PM   (building)
üü£ Week 5+  ‚Üí 1000mg AM + 1000mg PM   (target)
```
*Only increase when you're tolerating well.*

## WHAT TO WATCH FOR

| Level | Signs | What to Do |
|-------|-------|------------|
| üü° Normal | Upset stomach, loose stools | Wait 2-4 weeks - this improves |
| üü† Call us | GI issues lasting >4 weeks, extreme tiredness | Schedule a visit |
| üî¥ Emergency | Trouble breathing, severe muscle pain, feeling very cold + slow heartbeat | Call 911 |

## CHECK-INS

| When | What We'll Ask |
|------|----------------|
| Day 3 | How's your stomach? Taking with food? |
| Day 7 | Tolerating okay? Any problems? |
| Day 14 | Ready to increase your dose? |
| Month 1 | How's it going? Any side effects? |
| Month 3 | A1c recheck - let's see your progress! |

## HOW OTHERS ARE DOING
‚≠ê 4.2/5 rating | 72% still taking at 6 months | 65% reached their goal

---

# üìã EXPANDED VIEW

> Everything you might want to know about your medication. Your care team uses this same information to guide you.

---

## UNDERSTANDING YOUR MEDICATION

**What is Metformin?**
Metformin is a diabetes medication that's been helping people for over 60 years. It's the most-prescribed diabetes medication in the world because it works well and is very safe.

**How does it work?**
Your body normally releases sugar from your liver and uses it for energy. With diabetes, your liver releases too much sugar. Metformin:
1. Tells your liver to release less sugar
2. Helps your muscles use sugar more efficiently
3. Slightly slows sugar absorption from food

**What makes it special?**
- Won't cause low blood sugar when taken alone
- Doesn't cause weight gain (many people lose a little weight)
- Protects your heart
- Very affordable
- 60+ years of safety data

---

## YOUR DOSING SCHEDULE

| Form | Sizes Available |
|------|-----------------|
| Immediate Release (IR) | 500mg, 850mg, 1000mg tablets |
| Extended Release (ER) | 500mg, 750mg, 1000mg tablets |

**Your schedule:** Twice daily - with breakfast and dinner
**Why with food?** Dramatically reduces stomach upset

**If you miss a dose:** Take it with your next meal. Never take two doses at once.

---

## WHAT TO EXPECT

### First 2-4 Weeks (Getting Started)
Many people experience stomach upset early on. This is normal and usually goes away:
- Upset stomach or nausea
- Loose stools or diarrhea
- Metallic taste in mouth

**These typically improve by week 3-4.** If they don't, we have solutions.

### After 1-3 Months
- More stable energy levels
- Fewer sugar cravings
- Your A1c will show improvement (even if you don't "feel" different)
- Possible mild weight loss

### Long-Term Benefits
- Lower blood sugar
- Reduced risk of diabetes complications
- Heart protection
- Better overall metabolic health

---

## MONITORING & LABS

| Test | How Often | Why |
|------|-----------|-----|
| A1c | Every 3 months ‚Üí every 6 months when stable | Shows your 3-month blood sugar average |
| Kidney function (eGFR) | Every 3-6 months initially ‚Üí yearly | Ensures kidneys are handling the medication well |
| Vitamin B12 | Yearly | Metformin can lower B12 over time |

**Your target:** A1c below 7.0% (or the goal your care team sets for you)

---

## WHEN TO PAUSE YOUR MEDICATION

There are specific times when you should temporarily stop taking Metformin:

| Situation | What to Do |
|-----------|------------|
| Getting a CT scan or MRI with contrast dye | Stop 48 hours before AND after the scan |
| Severely sick with vomiting/diarrhea/dehydration | Hold until you're better |
| Having surgery | Hold the day of your procedure |

**When in doubt, call us.** You can always restart when the situation resolves.

---

## LIFESTYLE & INTERACTIONS

**Food:** Take with meals. Avoid very greasy foods initially if you're having stomach issues.

**Alcohol:** Limit to 1-2 drinks per day. More than that increases risks.

**Other medications to be aware of:**
- If you take regular NSAIDs (ibuprofen, naproxen), your kidney function should be monitored
- Always tell any doctor or imaging center that you take Metformin before contrast scans

---

## COMMON QUESTIONS

**"I don't feel any different. Is it working?"**
Metformin works silently in the background. Most people don't "feel" their blood sugar changing - that's why we check A1c. Think of it like blood pressure medication: you don't feel it working, but it is.

**"My stomach is really upset. Should I stop?"**
Not yet! This is the most common early side effect and usually improves by week 3-4. Try eating more food with your pill and avoiding greasy foods. If it doesn't improve after 4 weeks, we can switch you to the extended-release version.

**"I forgot my pills for a few days. What now?"**
Just restart with your next meal. No need to make up missed doses. Mention it at your next check-in.

**"Can I ever stop taking this?"**
For some people, yes. If your A1c drops to normal range (under 5.7%) and stays there for 6 months with good lifestyle habits, we can discuss a supervised taper. This is uncommon but possible.

---

## WHEN TO REACH OUT

**Schedule a visit for:**
- Stomach issues that haven't improved after 4 weeks
- Extreme tiredness
- Questions about your progress

**Seek immediate care for:**
- Difficulty breathing
- Severe muscle pain
- Feeling very cold with slow heartbeat
- Signs of severe dehydration

---

## YOUR PROGRESS TRACKER

**Your starting A1c:** _____ | **Date started:** _____

**Milestones:**
- [ ] First week completed
- [ ] Target dose reached (1000mg twice daily)
- [ ] First A1c recheck (Month 3)
- [ ] A1c at goal (< 7.0%)

---

# üìö EVIDENCE

> Why you can trust this recommendation.

**Bottom line:** Metformin is the world's most trusted diabetes medication, recommended as first choice by every major medical organization.

| Source | What They Say |
|--------|---------------|
| **American Diabetes Association** | "Preferred initial medication for Type 2 diabetes" |
| **60+ Years of Use** | Billions of doses prescribed safely worldwide |
| **Major Clinical Trials** | 32% reduction in diabetes complications |

**Evidence Grade: A** (Strongest possible)

---

# üè• CLINICIAN & AI REFERENCE

> Clinical decision support for care teams. AI-readable specifications below.

---

## CLINICAL SUMMARY

### Overview
Metformin hydrochloride (Glucophage) is a biguanide antihyperglycemic agent that remains the preferred first-line pharmacologic therapy for Type 2 diabetes mellitus per ADA, EASD, and AACE guidelines. Mechanism includes hepatic gluconeogenesis suppression, enhanced peripheral insulin sensitivity, and delayed intestinal glucose absorption.

### Key Clinical Points
- **A1c reduction:** 1.0-1.5% from baseline
- **Cardiovascular benefit:** Only oral diabetes agent with proven mortality reduction (UKPDS)
- **Weight effect:** Neutral to slight loss (contrast to sulfonylureas, TZDs)
- **Hypoglycemia risk:** Minimal as monotherapy
- **NNT:** 14 to prevent one complication over 10 years

### Contraindications
- eGFR < 30 mL/min/1.73m¬≤
- History of lactic acidosis
- Acute decompensated heart failure
- Severe hepatic impairment

### Renal Dosing
| eGFR | Recommendation |
|------|----------------|
| ‚â• 60 | Full dose |
| 45-59 | Full dose, monitor q3-6mo |
| 30-44 | Max 1000mg/day, monitor q3mo, avoid initiation if <45 |
| < 30 | Contraindicated |

### Common Drug Interactions
| Agent | Severity | Management |
|-------|----------|------------|
| Iodinated contrast | High | Hold 48h before and after; verify eGFR before resuming |
| Chronic NSAID use | Moderate | Monitor renal function |
| Alcohol (excessive) | Moderate | Counsel limitation; increases lactic acidosis risk |
| Carbonic anhydrase inhibitors | Moderate | May increase lactic acidosis risk |

### Monitoring Protocol
| Parameter | Frequency |
|-----------|-----------|
| A1c | q3mo until stable ‚Üí q6mo |
| eGFR/Cr | q3-6mo initially ‚Üí annually |
| Vitamin B12 | Annually (deficiency in 5-10% long-term) |

### Treatment Failure Considerations
If A1c not at goal after 3 months at maximum tolerated dose:
- **With ASCVD/high CV risk:** Add SGLT2i (empagliflozin, dapagliflozin) or GLP-1 RA
- **With CKD/proteinuria:** Add SGLT2i
- **With obesity priority:** Add GLP-1 RA (semaglutide, tirzepatide)
- **Cost constraints:** Add sulfonylurea or TZD

### Evidence Base
| Study | Design | Key Finding |
|-------|--------|-------------|
| UKPDS 34 | RCT, n=1,704, 10yr | 32% reduction in diabetes-related endpoints, 36% all-cause mortality reduction in overweight patients |
| HOME Study | RCT, n=390 | CV benefit in insulin-treated T2DM |
| Cochrane 2012 | Meta-analysis, 35 RCTs | Confirmed 1.0-1.5% A1c reduction |

**Evidence gaps:** Limited RCT data for eGFR 30-45; no large head-to-head trials vs newer agents as first-line.

### Feasibility Score: 75/100

| Factor | Points |
|--------|--------|
| Baseline | 100 |
| GI tolerability concerns | -15 |
| BID dosing requirement | -5 |
| Lab monitoring | -5 |
| Low cost/affordability | +10 |
| No hypoglycemia risk | +5 |
| Weight neutral | +5 |

### Patient Confidence Assessment
Ask at prescribing: "On a scale of 0-10, how confident are you that you can take this medication twice daily with meals?"

| Score | Interpretation | Action |
|-------|----------------|--------|
| 8-10 | High confidence | Proceed with standard initiation |
| 5-7 | Moderate confidence | Explore barriers, consider additional support |
| 0-4 | Low confidence | Address barriers before starting; may need motivational interviewing |

---

## AI METADATA

<!--
AI-readable specifications for automated processing.
Clinicians: The above reference section summarizes this data in readable format.
-->

```yaml
# === IDENTIFIERS ===
card_id: MED_DM_BIG_001
generic: Metformin Hydrochloride
brand: Glucophage
class: Biguanide
path: Medical > Medications > Diabetes > Biguanides

# === CARE PLAN CONTEXT ===
care_plan:
  typical_plan_type: chronic  # First-line diabetes medication for long-term use
  clinical_intent: protect    # Protects against diabetes complications and CV events
  time_interval: daily        # Taken twice daily
  specialist_owner: Endocrinologist_AI  # Metabolic/diabetes specialist
  max_concurrent_behavioral: 3  # Standard 3-card rule

# === AUTONOMY ===
autonomy:
  tier: 4  # Clinician-directed
  responsible_agent: AI_Pharmacist
  specialist_consult: AI_Endocrinologist
  approval_type: individual
  patient_can_initiate: false
  patient_can_adjust: false
  patient_can_pause: true  # AI alerts clinician
  patient_can_discontinue: false  # Requires approval

# === TAGS ===
tags:
  clinical: [diabetes, T2DM, metabolic, first_line]
  evidence: [grade_A, guideline_recommended, RCT_supported]
  properties: [oral, BID, titratable, chronic]
  systems: [metabolic, cardiovascular]

# === RELATED CARDS ===
related:
  alternative: MED_DM_BIG_002  # Metformin ER - if GI intolerant
  add_on:
    - MED_DM_SGLT2_001  # Empagliflozin - if CV/renal benefit needed
    - MED_DM_GLP1_001   # Semaglutide - if weight loss priority
  synergy:
    - DIAG_LAB_A1C      # A1c monitoring
    - BEHAV_NUT_xxx     # Nutrition cards
    - BEHAV_MOV_xxx     # Movement cards
  prerequisite: none
  leads_to: [SGLT2i, GLP1]  # If inadequate response

# === DOSING ===
dosing:
  forms: [500mg, 850mg, 1000mg]
  route: PO
  frequency: BID
  with_food: required
  start: 500mg BID
  target: 1000mg BID
  max: 2550mg/day
  titration:
    interval: 1-2 weeks
    increment: 500mg

# === CONTRAINDICATIONS ===
contraindications:
  - eGFR < 30
  - lactic_acidosis_history
  - acute_decompensated_HF
  - severe_hepatic_impairment

# === ADJUSTMENTS ===
adjustments:
  renal:
    - condition: eGFR 30-45
      action: max 1000mg/day, monitor q3mo
    - condition: eGFR 45-60
      action: full dose, monitor q3mo
  age:
    - condition: age > 75
      action: start 500mg daily, slow titration
  GI_history:
    - condition: prior_intolerance
      action: start 500mg daily, consider ER

# === HOLD CONDITIONS ===
hold:
  - condition: IV_contrast
    action: hold 48h before and after
    auto_resume: yes, if eGFR stable
  - condition: acute_illness_dehydration
    action: hold until resolved
  - condition: surgery_NPO
    action: hold day of procedure

# === INTERACTIONS ===
interactions:
  - drug: alcohol
    severity: moderate
    action: counsel limit 1-2 drinks
  - drug: NSAIDs_chronic
    severity: moderate
    action: monitor eGFR
  - drug: contrast_IV
    severity: high
    action: hold protocol

# === MONITORING ===
monitoring:
  A1c: {initial: q3mo, stable: q6mo}
  eGFR: {initial: q3mo, stable: annually}
  B12: annually

# === ALERTS ===
alerts:
  efficacy:
    - condition: A1c drop < 0.5% after 3mo max dose
      action: recommend add second agent
      urgency: routine
  safety:
    - condition: eGFR decline > 25%
      action: flag for clinician review
      urgency: urgent
    - condition: eGFR < 30
      action: discontinue, alert clinician
      urgency: urgent
  tolerability:
    - condition: GI symptoms > 4 weeks
      action: recommend switch to ER
      urgency: routine
  adherence:
    - condition: missed 3+ consecutive
      action: barrier assessment
      urgency: routine
    - condition: adherence < 50% over 14 days
      action: escalate to care team
      urgency: soon

# === PROACTIVE CHECK-INS ===
checkins:
  initiation:
    - day: 3
      questions: [gi_tolerance, taking_with_food]
      escalate_if: severe_gi
    - day: 7
      questions: [tolerating, barriers]
      escalate_if: persistent_gi, non_adherence
    - day: 14
      questions: [ready_to_advance]
      action_if_ready: advance_dose
  titration:
    - week: 4
      focus: dose_advancement
    - week: 8
      focus: adherence_check
  maintenance:
    - interval: monthly
      focus: adherence_symptoms
    - interval: quarterly
      focus: a1c_egfr_comprehensive

# === LIFECYCLE ===
lifecycle:
  initiation:
    duration: days 1-14
    focus: tolerability
    success: tolerating BID, no severe GI
  maintenance:
    adherence_target: 80%
    review: monthly app, quarterly visit
  de_loading:
    graduation:
      criteria: A1c < 5.7% sustained 6mo + lifestyle
      action: supervised taper
      rare: true
    transition_gi:
      criteria: GI intolerable > 4 weeks
      action: switch to MED_DM_BIG_002
    transition_efficacy:
      criteria: A1c not at goal after 3mo max dose
      action: add SGLT2i or GLP-1
    discontinue:
      criteria: [eGFR < 30, lactic_acidosis, patient_refusal]
      action: stop, document, alternative

# === EVIDENCE (AI Reference) ===
evidence:
  grade: A
  last_reviewed: 2024-12
  primary_guideline: ADA_Standards_2024
  key_trials: [UKPDS_34, HOME]
  meta_analyses: [Cochrane_2012]
  evidence_gaps: [eGFR_30-45_RCT, first_line_vs_newer_agents]

# === FEASIBILITY ===
feasibility:
  score: 75
  difficulty: easy  # Patient-facing
  deductions: {GI_effects: -15, BID_dosing: -5, monitoring: -5}
  boosters: {affordable: +10, no_hypoglycemia: +5, weight_neutral: +5}
```

---

**END OF CARD**

### Version History
| Version | Date | Changes |
|---------|------|---------|
| 0.5 | 2025-12-13 | Major revamp: Restructured sections for audience clarity (Patient views, Clinician reference, AI metadata) |
| 0.4 | 2025-12-12 | Added care_plan context block |
| 0.3 | 2025-12-08 | Added At-a-Glance quick card, visual dose ladder, decision pathway |
| 0.2 | 2025-12-07 | Added AI agent specifications, Evidence section |
| 0.1 | 2024-11-23 | Initial card |

**Note:** v1.0 will be assigned at first production deployment with real patients.

*Template: Universal Card Template v0.5*
